C12N 2710/10362
By genetic engineering
Official title: by genetic engineering
C12N2710/10362 (By genetic engineering) appears on 42 US grants and 40 published applications in this corpus.
Search patents in C12N- Granted patents
- 42
- Published applications
- 40
- Assignees
- 32
- Inventors
- 117
- Latest grant
- 28 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 7 | 0 |
| 2000 | 5 | 0 |
| 2001 | 3 | 1 |
| 2002 | 2 | 2 |
| 2003 | 1 | 6 |
| 2004 | 0 | 2 |
| 2005 | 2 | 3 |
| 2006 | 2 | 2 |
| 2007 | 1 | 1 |
| 2008 | 1 | 1 |
| 2009 | 1 | 1 |
| 2010 | 1 | 0 |
| 2011 | 0 | 1 |
| 2012 | 2 | 3 |
| 2013 | 1 | 2 |
| 2014 | 1 | 1 |
| 2015 | 2 | 1 |
| 2016 | 0 | 0 |
| 2017 | 1 | 1 |
| 2018 | 1 | 1 |
| 2019 | 0 | 2 |
| 2020 | 1 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 2 |
| 2023 | 0 | 3 |
| 2024 | 0 | 2 |
| 2025 | 2 | 1 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist28 Apr 2026US 12,611,453 B2Gilead Sciences, Inc.
- Adenosomes7 Oct 2025US 12,435,110 B2Erasmus University Medical Center Rotterdam
- Adenoviral vector transduced apheresis product15 Apr 2025US 12,274,748 B2ImmunityBio, Inc.
- Human type 55 replication defective adenovirus vector, method for preparing same and uses thereof1 Sep 2020US 10,760,096 B2Guangzhou N Biomed Co., Ltd.
- Adenovirus vaccine vectors9 Jan 2018US 9,862,931 B2Institut Gustave Roussy
- Adenoviral vector vaccine against respiratory syncytial virus, and preparation method therefor and use thereof1 Jan 2026US 2026/0000746 A1Cansino Biologics Inc.
- Adenoviral Vector Transduced Apheresis Product31 Jul 2025US 2025/0242025 A1ImmunityBio, Inc.
- Adenoviral Vector Transduced Apheresis Product7 Nov 2024US 2024/0366764 A1ImmunityBio, Inc.
- Use of oncolytic adenovirus for the treatment of pediatric brain cancer4 Jul 2024US 2024/0216492 A1
- Method for preparing adenovirus vector vaccine by means of perfusion culture process5 Oct 2023US 2023/0313225 A1Cansino Biologics Inc.
Most cited
By later US patents
- Defective adenoviruses and corresponding complementation lines113US 6,040,174 ATransgene S. A. · 2000
- Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use102US 7,247,472 B2The Trustees of the University of Pennsylavania · 2007
- Cytopathic viruses for therapy and prophylaxis of neoplasia87US 5,846,945 AOnyx Pharmaceuticals, Inc. · 1998
- Cells for the production of recombinant adenoviruses85US 6,127,175 ARhone-Poulenc Rorer S.A. · 2000
- Cytopathic viruses for therapy and prophylaxis of neoplasia74US 5,677,178 AOnyx Pharmaceuticals, Inc. · 1997